KR101616995B1 - Composition for slimming - Google Patents

Abstract

The present invention relates to a composition for slimming comprising interleukin-17 (IL-17) as an active ingredient. The slimming effect can be exerted through inhibition of the differentiation of the fat cells, which is an effective ingredient of the composition for slimming according to the present invention, and reduction of lipid levels in differentiated adipocytes.

Description

COMPOSITION FOR SLIMMING [0002]

The present invention relates to a composition for slimming, and more particularly, to a composition for slimming to inhibit differentiation of adipocytes or reduce lipid levels in adipocytes.

Interleukin-17 (IL-17) is a type of cytokine, also known as cytotoxic T-lymphocyte-associated serine esterase (CTLA8).

On the other hand, various diseases including obesity or lipomas are known to be related to abnormal lipid differentiation or lipid body content in adipocytes. Accordingly, studies on lipid differentiation and lipid body content in adipocytes have been actively conducted, and development of factors or substances capable of effectively controlling lipid differentiation or lipid level in adipocytes is required.

Thus, the present inventors have tried to discover such factors or substances, and have found that IL-17 not only effectively inhibits the differentiation of mesenchymal stem cells into adipocytes, but also reduces lipid levels in already differentiated adipocytes Thereby completing the present invention.

Accordingly, it is an object of the present invention to solve the technical problems requested from the past.

Specifically, an object of an embodiment of the present invention is to provide a composition for slimming comprising interleukin-17 (IL-17), which is effective for inhibiting adipocyte differentiation, as an active ingredient.

Another object of the present invention is to provide a composition for slimming comprising interleukin 17 as an active ingredient capable of reducing lipid in adipocytes.

To achieve the above object, the composition for slimming according to the present invention is characterized by containing interleukin-17 (IL-17) as an active ingredient.

It is confirmed from the present invention that IL-17 inhibits adipocyte differentiation and reduces lipid levels in adipocytes. Thus, the composition according to the present invention containing IL-17 as an active ingredient has excellent The slimming effect can be exhibited.

FIGS. 1 to 4 are micrographs and graphs showing the effect of inhibiting adipocyte differentiation of IL-17A or IL-17F, according to one embodiment of the present invention;
5 to 10 are graphs showing changes in the expression of IL-17RA and IL-17RC mRNA by IL-17A or IL-17F and the expression of PPARgamma, FABP4 and adiponectin in cells treated with IL-17A according to an embodiment of the present invention Lt; RTI ID = 0.0 > mRNA < / RTI >
FIGS. 11 and 12 are graphs showing the results of observing the inhibitory effect of IL-17A on adipocyte differentiation through anti-IL-17A, according to an embodiment of the present invention;
FIGS. 13 to 15 are photomicrographs and graphs showing the results of quantitative measurement of lipid levels in adipocytes, according to one embodiment of the present invention;
16 to 19 are graphs showing the results of evaluating whether IL-17A regulates the expression of IL-6 and IL-8 genes in differentiated adipocytes, according to an embodiment of the present invention;
FIG. 20 is a graph showing the relationship between the amount of epididymal adipose tissue mass and the number of epididymal adipose tissues after 7 days of injecting IL-17A into the right epididymal adipose tissue of C57BL / 6 mice in which obesity was induced by consuming one month of high fat diet according to an embodiment of the present invention When measured, it showed a decrease in adipose tissue.

The term " slimming " as used in the present invention is intended to include not only alleviation or prevention of obesity but also prevention or treatment of diseases associated with an increase in fat tissue, weight loss for cosmetic or plastic purposes, And is not particularly limited as long as it does not violate the above object in a broad sense including all the elastic and smooth skin conditions of the body made by alleviating or preventing the formation of the bending body state.

When the inventors of the present application include at least one selected from the group consisting of interleukin-17, IL-17, IL-17A and IL-17F as an active ingredient of the composition, And lipid droplet levels in the fat cells that have already been differentiated can be reduced.

Interleukin-17 is a cytokine, interleukin 6, IL-6, interleukin 8, IL-8, and granulocyte colony stimulating factor, which are known cytokines that affect the differentiation of hematopoietic system in human fibroblasts (IL-17: a novel cytokine-derived T cells, J. Immun. 155: 5483-5486, 1995), which is known to increase the expression of granulocyte colony stimulating factor (G-CSF) . In addition, interleukin 17 plays a role in regulating T-cell-mediated immune responses that are associated with allergic responses, which has been demonstrated from experiments using mice deficient in IL-17 (Nakae et al., Suppression of immune Induction of collagen- induced arthritis in IL-17-deficient mice. J. Immun. 171: 6173-6177, 2003). In addition, IL-17 is also thought to affect the onset of arthritis, as IL-17 deficient mice have been reported to be less likely to induce collagen-induced arthritis (Nakae et al., IL- 17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist Proc Nat. Acad Sci., 100: 5986-5990, 2003). In particular, IL-17 has been reported to be associated with the onset of rheumatoid arthritis because IL-17 is reported to be present at a higher concentration in the synovial fluid of patients with rheumatoid arthritis compared to patients with osteoarthritis (Kotake et al., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J. Clin. Invest. 103: 1345-1352, 1999).

Despite these many studies, it has not been reported that a composition containing IL-17 (IL-17) as an active ingredient can exert an excellent slimming effect.

The interleukin 17 may include one or more selected from the group consisting of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. A composition comprising at least IL-17A and IL-17F selected from the group consisting of IL-17A and IL-17A as an active ingredient can exert an especially excellent slimming effect.

In one embodiment, the composition may be one that inhibits the differentiation of adipocytes by IL-17A or IL-17F, among which interleukin 17 as an active ingredient, Preventing or treating diseases associated with hypertrophy, or exhibiting an effect of reducing fat tissue for cosmetic or cosmetic purposes. The disease associated with hypertrophy of the adipose tissue is not particularly limited, but can be, for example, obesity and lipoma,

The ability of the IL-17A or IL-17F to inhibit the differentiation of adipocytes can be confirmed by the following experimental examples. In the differentiation of adipocytes treated with IL-17A or IL-17F, PPARgamma (peroxisome proliferator activating 17A or IL-17F, which is expressed by a decrease in the expression level of at least one adipocyte-related gene selected from the group consisting of adiponectin mRNA, FABP4 (fatty acid binding protein 4) mRNA and adiponectin mRNA. Lt; RTI ID = 0.0 > differentiation < / RTI > of adipocytes can be effectively inhibited.

The adipocyte differentiation may be that an adipose precursor cell or mesenchymal stem cell of an animal, preferably a mammal, is differentiated into an adipocyte, more preferably a mesenchymal stem cell of a human is differentiated into an adipocyte .

The mesenchymal stem cells are widely used in the study of adipocyte differentiation because they can be differentiated into adipocytes by almost the same method as the method of differentiating the adipocyte precursor cells collected from subcutaneous tissues into complete adipocytes. The mesenchymal stem cells, which are known to be able to differentiate into other types of cells such as chondrocytes or bone cells as well as adipocytes, are distributed in most tissues of the body. The mesenchymal stem cells are most preferably similar to the mesenchymal stem cells derived from the human bone marrow. The term " mesenchymal stem cells " .

In one embodiment, the composition may be one that reduces the size and number of lipid droplets in differentiated adipocytes. As demonstrated by the following experimental examples, the level of lipid and the degree of lipid degradation of IL-17, especially IL-17A, were measured by measuring glycerol concentration. As a result, it was confirmed that the size and number of lipid bodies were reduced And lipid degradation of adipocytes was also significantly increased.

The composition for slimming according to the present invention can be formulated into, for example, a cosmetic composition, a health food composition or a pharmaceutical composition.

The composition of the slimming cosmetic composition is not particularly limited and may be in the form of a softening agent, a nutritional lotion, a nutrition lotion, a massage cream, a nutritional cream, a pack, a gel, a body lotion, a body cream, a body oil or a body essence And the cosmetic composition of each formulation can be mixed with other ingredients other than IL-17A or IL-17F without difficulty by those skilled in the art depending on the purpose of formulation or use.

The formulation for the slimming health food composition is not particularly limited, but may be formulated into, for example, tablets, granules, drinks, caramels, diet bars and the like. The health food composition of each formulation may be formulated by those skilled in the art without difficulty, depending on the purpose of formulation or use, in addition to the IL-17A or IL-17F described above. If the composition is applied simultaneously with other ingredients A synergistic effect can occur.

The pharmaceutical composition for slimming may further contain a preservative, a stabilizer, a wetting agent or an emulsifying accelerator, a pharmaceutical adjuvant such as a salt and / or a buffer for controlling osmotic pressure, and other therapeutically useful substances, May be formulated in a variety of oral or parenteral dosage forms.

Examples of the formulations for oral administration include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, granules, etc. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, Sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g., silica, talc, stearic acid and magnesium or calcium salts thereof, and polyethylene glycols). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. Tablets can be prepared by conventional mixing, granulating or coating methods.

In addition, a representative aqueous solution for parenteral administration is preferably an isotonic aqueous solution or suspension in a form of injection. In the case of the parenteral administration form, 0.00001 mg / kg to 0.01 mg / kg, preferably 0.00001 mg / kg to 0.001 mg / kg, can be administered locally to a site having a parenteral route or adipose tissue.

The dosage of the active ingredient is within the level of those skilled in the art. Generally, the dosage is 0.001 mg / kg / day to 2000 mg / kg / day, preferably 0.5 mg / kg / day to 2.5 mg / kg / day. However, it should be understood that the actual dosage should be determined in accordance with various relevant factors such as the severity of the symptoms, the route of administration chosen, the age, sex, weight and health status of the subject, It does not limit the scope.

In addition, IL-17A or IL-17F used as the active ingredient is preferably contained in an amount of 0.001 to 100% by weight based on the total weight of the composition, and the active ingredient is contained in an amount of 100% , IL-17A or IL-17F is maintained in a form suitable for exhibiting a slimming effect, meaning that the protein itself can be used in a composition for slimming.

The IL-17 may be, but is not limited to, a mammal, more preferably a human, and may be recombinant IL-17 produced by recombinant techniques, or purified natural IL-17, I) an amino acid sequence of SEQ ID NO: 1; Ii) a fragment of the amino acid sequence of SEQ ID NO: 1, having the same slimming activity as SEQ ID NO: 1; Or iii) a variant of the amino acid sequence of SEQ ID NO: 1, which has 95% or more homology with the sequence of SEQ ID NO: 1, and which has the same slimming activity as SEQ ID NO: 1.

As used herein, "fragment" means having a slimming activity, and such fragments may be produced by known enzyme cleavage or by recombinant techniques.

As used herein, "variant" means an amino acid in which the complementarity of an amino acid is altered by at least one or more amino acids. Those skilled in the art will appreciate that all variants determined to possess slimming activity by specifically binding to IL-17 having slimming activity by producing and testing variants of the amino acids described herein are within the scope of the present invention.

Such variants also include variants that preserve the overall molecular structure of the amino acid sequence. Given information about the properties of individual amino acids, one of ordinary skill in the art will recognize some reasonable substitutions. Such conservative substitutions can be performed, for example, on the basis of the polarity, charge, solubility, hydrophobicity, hydrophilicity and / or amphipathic nature of the related residues. For example, amino acids can be classified into nonpolar (hydrophobic) amino acids, polar neutral amino acids, bipolar charged (basic) amino acids, and negatively charged (acidic) amino acids, depending on the polarity. Non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Bipolar charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Within each of the above groups, substitutions can be made conventionally.

"Sequence" disclosed herein may include sequences of SEQ ID NO: 1 encoding the amino acids described herein, as well as variants thereof. The "variant" may have a sequence homology of 80% or more. In addition, it may have 90% or more or 95% or more of the sequence homology. Among such mutants having the above homology, there are variants in which hybridization occurs even under very high stringency conditions.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the present invention, but the scope of the present invention is not limited thereto.

[Experimental Example 1] Effect of IL-17 on adipocyte differentiation of human bone marrow mesenchymal stem cells

Human bone marrow mesenchymal stem cells (hBM-MSCs) were purchased from Lonza, Inc. (Walkersville, MD, USA) and cultured according to Lonza's guidelines. More specifically, human bone marrow mesenchymal stem cells (hBM-MSCs) were treated with 10% fetal bovine serum, 1% penicillin / streptomycin and 1% glutamax (Invitrogen, Carlsbad, Calif., USA) in a low glucose (1 g / L) medium (Dulbecco's modified eagle's medium (DMEM) When the cell density in the culture dish reached 100%, the conditions for differentiating into adipocytes were changed. 1 μg / ml of insulin, 1 μM of Dexamethasone (DEXA), and 1 μM of 3-isobutyl-1-methylxanthine (3- 0.5 mg of isobutyl-1-methylxanthine, IBMX) and troglitazone (T) (hereinafter referred to as IDXT), and human bone marrow mesenchymal stem cells were differentiated into adipocytes for 14 days.

In the experimental group, IDXT and 25 ng / ml of IL-17A, IL-17F or IL-22 were added to the medium for induction of adipocyte differentiation and treated for 15 days. After 15 days from the start of differentiation, the cell culture medium was removed, and the cells were washed with 10 ml of phosphate buffer (PBS). Cells were washed with 10% formalin / PBS solution (0.2 ml / cm ²⁾ Lt; / RTI > The fixed cells were washed once with a 60% isopropanol solution (0.5 ml / cm ² ), and the lipid in the adipocyte was stained with 0.2 ml / cm ² of a dye solution obtained by dissolving Oil Red O in 60% isopropanol Respectively. Subsequently, re-staining with hematoxylin was carried out to easily distinguish the nucleus. The result was observed with a microscope and the result of comparison with a control (control) treated with IDXT alone is shown in FIG.

In order to measure the degree of differentiation of adipocytes, the adipocytes were stained with Oil Red Oto, and then the dyed oil red oe was eluted with a 100% isopropanol solution. Then, the absorbance was measured at a wavelength of 500 nanometers (nm) Respectively.

1 and 2, it was confirmed that IL-17A or IL-17F can inhibit the differentiation to 77.6% and 45.6%, respectively, as compared with the control group treated with IDXT alone. However, when 25 ng / mL IL- 22 did not show statistically significant inhibitory effect on adipocyte differentiation.

The inhibitory effect of different cytokines of IL-17 on adipocyte differentiation was measured and shown in Fig.

As shown in FIG. 3, IL-17B, IL-17D or IL-17E did not exhibit a specific inhibitory effect in comparison with IL-17A and IL-17F, Respectively.

Thereafter, it was confirmed whether or not IL-17A showed a concentration-dependent inhibition of differentiation, and the results are shown in FIG.

4, IDXT and IL-17A of 25, 5 or 1 ng / mL were inhibited to 81.9, 75.6 or 46.2%, respectively, as compared with the control group treated with IDXT alone, indicating that IL-17A And thus inhibits adipocyte differentiation in a concentration-dependent manner.

[Experimental Example 2] Whether IL-17A affects the transcription level of IL-17RC and IL-17RA

IL-17 was treated at a concentration of 1 ng / ml for 7 days in human bone marrow mesenchymal stem cells that induced differentiation into adipocytes by the same method as described in Example 1, and then treated with triazol reagent (Trizol reagent, Invitrogen, Carlsbad, CA, USA). The separated RNA was further purified with an RNA kit (Qiagen RNeasy kit, Qiagen, Valencia, Calif.) From Agilent Technologies, Inc. (Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, Calif. Were used to confirm the quality of the RNA. Reverse transcription polymerase chain reaction (RT-PCR) was performed using the reverse transcription kit (Invitrogen, Carlsbad, Calif.) Of Invitrogen. Q-RT-PCR). IL-17RA and IL-17RC, which are transmembrane receptor proteins induced by IL-17A at early stages of adipocyte differentiation, are known to play an important role in IL-17A and IL-17F signaling, (TaqMan gene expression assay kit, Applied Biosystems, Foster City, Calif.). The results were shown in FIGS. 5 and 6 .

FIG. 5 shows that IL-17RA and IL-17RC mRNA expression levels were increased in both human myelinated mesenchymal stem cells differentiated into adipocytes and human myelinated mesenchymal stem cells differentiated into adipocytes. However, after 5 days of inducing differentiation, there was no specific difference between IL-17 RA mRNA in the non-differentiated control, differentiated human myeloid mesenchymal stem cells treated with IDXT, and IL-17A treated cells in the presence of IDXT .

6, the expression of IL-17RC gene was more than 2-fold higher in IDXT-treated cells than in the non-differentiated control group. This confirms that the expression level of IL-17RC mRNA is significantly affected by the presence of IL-17A.

In addition, changes in the expression pattern of the adipocyte-related gene on IL-17A were evaluated using a TaqMan gene expression assay kit (Applied Biosystems, Foster City, Calif.) Of Fried Biosystems, Inc. Are shown in FIGS. 7 to 9: leptin (Hs00174877_ml), leptin receptor (Hs00174497_ml), adiponectin Hs00605917_ml, FABP4 (fatty acid binding protein 4: Hs00609791_ml), PPARγ (peroxisome proliferator activating receptor γ: Hs00233423_ml).

7 to 9, it was confirmed that mRNA expression levels of PPARγ, FABP4, and adiponectin were significantly decreased in cells treated with IDXT and IL-17A 5 days after the start of adipocyte differentiation compared to IDXT control have.

10, when IL-17A was treated with the same cell culture medium used for Q-RT-PCR analysis, adiponectin protein secretion was remarkably reduced compared to the group treated with IDXT alone.

[Experimental Example 3] Confirmation of whether the effect of IL-17A on human bone marrow mesenchymal stem cells is neutralized by Anti-IL-17A

It was confirmed whether anti-IL-17A could neutralize the inhibitory effect of IL-17A on human bone marrow mesenchymal stem cells, and the results are shown in Figs. 11 and 12.

Referring to FIG. 11, 250 ng / mL anti-IL-17A abrogated IL-17A mediated adipocyte differentiation inhibition. To confirm these observations, levels of adiponectin in human bone marrow mesenchymal stem cells cultured under various lipogenic conditions were measured by ELISA, and the results are shown in FIG. 3B.

Referring to FIG. 12, IL-17A inhibited the secretion of adiponectin, and the effect was remarkably reduced by simultaneously treating the anti-IL-17A antibody. These results indicate that IL-17A plays an important role in inhibiting adipocyte differentiation in human bone marrow mesenchymal stem cells.

[Experimental Example 4] Effect of IL-17A on lipid levels in differentiated adipocytes

Human bone marrow mesenchymal stem cells were cultured in the same manner as in Experimental Example 1, and adipocyte differentiation was induced, followed by treatment with 25 ng / ml IL-17A. Adipocyte differentiation was induced in human bone marrow mesenchymal stem cells for 15 days and treated with IL-17 A for 7 days at the time when 50% or more cells were differentiated into adipocytes.

To quantitatively measure the level of lipid in the differentiated adipocytes and observe with a microscope, oil red staining / hematoxylin re-staining and absorbance measurement were carried out and the results are shown in Figures 13-15.

Referring to Figures 13 and 14, IL-17A reduced both the size and number of lipids in differentiated adipocytes. In order to measure the level of lipolysis, the concentration of glycerol contained in the supernatant from differentiated adipocyte cultures was measured and the results are shown in Fig.

FIG. 15 shows that IL-17A significantly increased lipid degradation of adipocytes. These results indicate that by controlling the lipid degradation of adipocytes differentiated with IL-17A, the metabolism state of differentiated adipocytes it is possible to confirm that the metabolic state is regulated.

[Experimental Example 5] Whether IL-17A affects the production of IL-6 and IL-8

In a non-immune cell such as keratinocyte and synoviocyte, pro-inflammatory IL-17A expresses a receptor that acts on IL-17A signaling, inflammatory effects of IL-6 and IL-8.

We evaluated whether IL-17A regulates the expression of IL-6 and IL-8 genes in differentiated adipocytes. Adipogenic differentiation was induced for 15 days and after 15 days, IL-6 mRNA levels were measured and the results are shown in 16 and 17.

16, the transcription of IL-6 under down-regulation of IDXT adipocytes was down-regulated compared to untreated human myeloid mesenchymal stem cells, and IDXT and 25 ng / mL IL-6 < / RTI > mRNA levels were significantly increased in differentiated adipocytes treated with IL-17A at the same time. Also, referring to FIG. 17, it can be seen that as the adipocyte differentiation progresses, the transcription level of IL-8 is remarkably increased as compared with the IDXT control group.

Furthermore, ELISA was used to confirm increased IL-6 and IL-8 protein production during adipocyte differentiation in human bone marrow mesenchymal stem cells, and the results are shown in FIG. Referring to FIG. 18, the expression of IL-6 and IL-8 at the protein level in adipocytes is increased when 25 ng / mL of IL-17A is treated.

19, IL-17 mRNA levels were up-regulated by treatment with IL-17F. However, no significant difference was observed between untreated cells and IL-17F treated cells And IL-8 showed similar patterns of expression in both protein secretion and gene expression when IL-17A and IL-17F were treated.

Thus, it can be confirmed that IL-17A modulates the production of IL-6 and IL-8 in differentiated adipocytes derived from human bone marrow mesenchymal stem cells.

[Experimental Example 6] Effect of IL-17A on the fat tissue mass in vivo

Four weeks old C57BL / 6 mice were treated with high-fat diet (AIN-93G 40%, method: Feedlap korea (www.feedlap.co.kr), composition L-cystine 3, TBHQ 0.14, choline bitartate 2, minerals mixture (see Table 1): casein 200, shortening 330, soybean oil 70, sucrose 100, dextrose 132, corn starch 48.7, cellulose 50, 50, vitamin mixture 14.3) to induce obesity, and mice weighing about 35 g were selected. The mice to be tested were prepared by dividing the selected mice into 2 experimental groups of 6 to 7 mice per group, and IL-17A to be injected was prepared by dissolving 1 μg of IL-17 in 1 ml of PBS and sterilizing by injection. One experimental group of mice was anesthetized with ketamine and 0.1 ml of the prepared IL-17A solution was injected into the epididymal fat bed of anesthetized mice using an injection of 26 gauge. In the control C57BL / 6 mice, only PBS was injected using the same procedure. After injection of IL-17A, the mice were fed a high fat diet for 7 days, and the mice were weighed and sacrificed. From the sacrificed mice, epididymal adipose tissue was collected and its mass was measured. The results are shown in FIG. As can be seen from FIG. 20, the mass of epididymal adipose tissues of mice in the experimental group injected with IL-17A was reduced compared with control mice injected with only PBS (see FIG. 20).

Hereinafter, formulation examples of the above composition will be described, but the present invention is not intended to be limited thereto but is specifically described.

[Formulation Example 1] Lotion preparation

IL-17A or IL-17F ............ 30.00 (%)

L-ascorbic acid-2-phosphate magnesium salt ............... 1.00

Water soluble collagen (1% aqueous solution) ........................ 1.00

Sodium citrate ....................................... 0.10

Citric acid ............................................ 0.05

Licorice extract .......................................... 0.20

1,3-butylene glycol ....................................... 3.00

maintain................................................. .2.00

Serine ................................................. .1.00

The whole amount was adjusted to 100 with purified water, and a lotion was prepared according to the compounding ratio (%).

[Formulation Example 2] Cream production

IL-17A or IL-17F ... 10.00 (%)

Polyethylene glycol monostearate ......................... 2.00

Self-emulsifying monostearic acid glycerin ...

Cetyl alcohol ................................................ .4.00

Squalane ................................................. ..6.00

Glyceryl tri-2-ethylhexanoate ...

Sphingo glycolipid ............................................... 1.00

1,3-Butylene glycol ............................................ 7.00

Vitamin C ................................................ .... 1.00

The whole amount was adjusted to 100 with purified water, and the cream was prepared in the above blending ratio (%).

[Formulation Example 3] Preparation of serum

IL-17A or IL-17F ..................... 20.00 (%)

Hydroxyethylene Cellulose (2% aqueous solution) ............... 12.00

Xanthan gum (2% aqueous solution) ............................... 2.00

1,3-butylene glycol .................................... 6.00

Dark glycerin ....................................... 4.00

Sodium hyaluronate (1% aqueous solution) ...................... 5.00

Maintain ................................................ 2.00

Serine ................................................ 1.00

Vitamin C ............................................ 1.00

The whole amount was adjusted to 100 with purified water, and a serum was prepared with the blending ratio (%).

[Formulation Example 4] Preparation of powder

IL-17A or IL-17F ............................ 100 mg

Lactose ................................................. ............ 100 mg

Talc ................................................. ............ 10 mg

maintain................................................. ............. 5 mg

The above components are mixed and filled in airtight bags to prepare powders.

[Formulation Example 5] Preparation of tablets

IL-17A or IL-17F ... 50 mg

Corn starch ................................................ 100 mg

Lactose ................................................. ....... 100 mg

Magnesium stearate .......................................... 2 mg

Vitamin C ................................................ ..... 50 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

[Formulation Example 6] Preparation of capsules

IL-17A or IL-17F ... 50 mg

Corn starch ................................................ 100 mg

Lactose ................................................. ...... 100 mg

Magnesium stearate ..................................... 2 mg

Vitamin C ................................................ .... 50 mg

Serine ................................................. ....... 50 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

[Formulation Example 7] Preparation of injection

IL-17A or IL-17F ... 50 mg

Sterile sterilized distilled water for injection .........................................

pH adjusting agent ................................................ .. Good

(2 ml) per 1 ampoule according to the usual injection preparation method.

[Formulation Example 8] Preparation of liquid agent

IL-17A or IL-17F ............................. 100 mg

Isolation Party ................................................ ..... 10 g

Mannitol ................................................. ...... 5 g

Vitamin C ................................................ ..... 50 mg

Serine ................................................. ......... 50 mg

maintain................................................. .........

Purified water................................................. ........

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

[Formulation Example 9] Preparation of health food

IL-17A or IL-17F ... 1000 mg

Vitamin mixture

Vitamin A Acetate ............................ 70 ㎍

Vitamin E ...................................... 1.0 mg

Vitamin B1 ....................................... 0.13 mg

Vitamin B2 ..................................... 0.15 mg

Vitamin B6 ........................................ 0.5 mg

Vitamin B12 .............................. 0.2 g

Vitamin C .......................................... 10 mg

Biotin ........................................... 10 μg

Nicotinic acid amide ....................................... 1.7 mg

Folic acid ............................................... 50 ㎍

Calcium pantothenate ....................................... 0.5 mg

Mineral mixture

Ferrous sulfate ........................................... 1.75 mg

Zinc oxide ............................................. 0.82 mg

Magnesium carbonate ...................................... 25.3 mg

Potassium phosphate monohydrate .......................................... 15 mg

Secondary calcium phosphate ...................................... 55 mg

Potassium citrate ............................................ 90 mg

Calcium carbonate .............................................. 100 mg

Magnesium chloride ...................................... 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

[Formulation Example 10] Preparation of health drink

IL-17A or IL-17F ............................ 1000 mg

Citric acid ................................................. ........ 1000 mg

oligosaccharide................................................. ........ 100 g

Plum concentrate ................................................ ......... 2 g

Taurine ................................................. ............ 1 g

Purified water was added to the whole ... 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (13)

IL-17A, IL-17A, and IL-17F as an active ingredient. IL-17A, IL-17A, and IL-17F as an active ingredient. A pharmaceutical composition for preventing or treating obesity or lipoma containing, as an active ingredient, interleukin-17 (IL-17) which is at least one selected from the group consisting of IL-17A and IL-17F. The method of claim 3,
Wherein said composition inhibits the differentiation of adipocytes. 5. The method of claim 4,
Wherein the adipocyte differentiation differentiates mesenchymal stem cells into adipocytes. 6. The method of claim 5,
Wherein said adipocyte differentiation differentiates mesenchymal mesenchymal stem cells into adipocytes. The method according to claim 1,
Wherein said composition reduces the number or size of lipid droplets in adipocytes. 3. The method of claim 2,
Wherein said composition reduces the number or size of lipid droplets in adipocytes. The method of claim 3,
Wherein said composition reduces the number or size of lipid droplets in adipocytes. The method of claim 3,
Wherein the active ingredient is contained in an amount of from 0.001 to 100% by weight based on the total weight of the composition. The method according to claim 1,
Wherein said IL-17 is recombinant IL-17 or purified natural IL-17. 3. The method of claim 2,
Wherein said IL-17 is recombinant IL-17 or purified natural IL-17. The method of claim 3,
Wherein said IL-17 is recombinant IL-17 or purified natural IL-17.

Images